ENTITY
CARsgen Therapeutics

CARsgen Therapeutics (2171 HK)

44
Analysis
Health Care • China
CARsgen Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, researching, and developing innovative CAR T-cell therapies. The company's pipeline includes therapies for hematological malignancies, solid tumors, and autoimmune diseases, such as CT053 for multiple myeloma. It is headquartered in Shanghai, China, and was founded in 2014.
more
Exchange Announcement • 13 Oct 2026 08:00

Voluntary Announcement - First Patient Dose Of Ct0596 In China Phase I Registrational Trial

Exchange Announcement • 30 Sep 2026 21:06

List Of Directors And Their Roles And Functions

Exchange Announcement • 30 Sep 2026 21:00

Resignation Of Non-Executive Director And Non-Compliance With Rule 3.21 Of The Listing Rules

Exchange Announcement • 29 Sep 2026 08:00

Voluntary Announcement - First Patient Dose Of Ct1190b In China Phase I Registrational Trial

Exchange Announcement • 15 Sep 2026 18:00

Interim Report 2026

x